Antibody Mediated Prevention (AMP) trials data published by the
New England Journal of Medicine
Most advanced clinical trials testing broadly neutralizing antibody against HIV demonstrate efficacy against sensitive strains
Public Relations Pacific LLC
E-Mail
SEATTLE - (EMBARGOED UNTIL MARCH 17, 2021, AT 5 P.M. ET) - The proof-of-concept AMP studies demonstrated that a broadly neutralizing antibody (bnAb) called VRC01 was effective at preventing the acquisition of HIV strains to the 30% of strains that were sensitive to the bnAb. This finding was seen both in Sub-Saharan Africa and the U.S. and South America. VRCO1 did not prevent the acquisition of HIV to strains that were resistant to the bNAb. As the resistant strains constituted nearly 70% of the circulating strains in these regions, there was no difference noted between the VRC01 arms and placebo arm in terms of overall prevention of HIV acquisition. The sensitivity to bNAbs was assessed by a laborat
As HIVR4P // Virtual comes to an end, here is a look at some of the highlights which emerged from the global scientific conference focused exclusively on HIV prevention research.
Founded in 1988, the International AIDS Society (IAS) is the world’s largest association of HIV professionals, with members from more than 180 countries working on all fronts of the global AIDS response. The IAS is also the steward of the world’s two most prestigious HIV conferences – the International AIDS Conference and the IAS Conference on HIV Science.
Founded in 1988, the International AIDS Society (IAS) is the world’s largest association of HIV professionals, with members from more than 180 countries working on all fronts of the global AIDS response. The IAS is also the steward of the world’s two most prestigious HIV conferences – the International AIDS Conference and the IAS Conference on HIV Science.